Navigation Links
Alacrita Asks "Are We All Biotech Now?"
Date:6/23/2011

LONDON, June 23, 2011 /PRNewswire/ --


 

Alacrita, which is changing the face of life science consulting, has published an insight into the future development of the global pharmaceutical industry. In the whitepaper, Alacrita sets out a vision of how the industry may look as it evolves in response to the challenges it faces and reflects on the decisions it has made. In particular, Alacrita considers whether the industry will reverse the unparalleled consolidation seen in the past 25 years to produce a diversity of strategically independent participants that operate along an extended pharma value chain. Such a split into distinct innovators, service providers and marketers would represent a wholesale adoption of the biotech model.

The article, written by Alacrita partners Anthony Walker and Rob Johnson, was published in the June issue of Business Development and Licensing Journal (Ref. 1) and is available at http://www.alacritaconsulting.com.

"The pharma industry has undergone significant change over the last decade as it has tried to maintain double digit growth and profitability in the face of decreasing R&D productivity, looming patent cliffs and increased focus on containing healthcare costs," said Dr Walker. "Aggressive M&A strategies haven't solved the problem, and we are seeing heightened activity in franchise management where portfolios are being vigorously reshaped through a combination of acquisition, licensing and partnering on the one hand, and project terminations and divestments on the other."  

"Pharma companies are increasingly becoming more focused and streamlined, with a greater emphasis on building core strengths and shedding non-core assets. Funds are being shifted to activities or functions that add the greatest value and if 'greatest value' requires a function to be carried out by an external party, then so be it," added Mr Johnson. "If the major pharma players are no longer one-stop shops and are streamlining themselves to focus on core capabilities, then where is this heading?"

As a result of its analysis, Alacrita proposes that the industry could transform itself into a series of smaller, focused and more dynamic enterprises, i.e.

  • Research and early development companies ('EarlyCos')
  • Late stage development, marketing and sales companies ('LateCos')
  • Functional service providers ('FSPs'), which undertake preclinical development, pharmaceutics, process development/manufacturing, etc.

Dr Walker added, "A greater drive towards outsourcing and more extensive deal-making will see the pharma industry further embracing the biotech model and leading to a highly competitive industry where only the strongest and fittest survive."

Reference

  1. A. Walker & R. Johnson, An alternative future for the pharmaceutical industry. Business Development and Licensing Journal (2011) Issue 15, 6-8.

About Alacrita Consulting

Alacrita is rapidly growing consultancy that provides tailored, value added solutions to clients in the pharmaceutical, biotechnology and life science sectors.

Alacrita applies its real-world expertise and experience to rapidly assess and understand the challenges faced by its clients and to develop solutions that exactly meet their needs. This blueprint is then used to access the Alacrita consultants best suited to deliver projects on time and on budget.

Alacrita provides its clients with access to consultants who combine extensive international industry experience (strategic, technical and commercial), broad functional capabilities and a track record of success across the life science sector.

In addition, Alacrita's network of more than 50 consultants with "hands on" management experience allows it to solve client resourcing needs at critical times in their corporate development.

Since inception, Alacrita and its network have completed successful consulting projects for big pharma, biotech companies, life science investors, government bodies and charities.

http://www.alacritaconsulting.com

For further information, please contact:

Anthony Walker or Rob Johnson, awalker@alacritaconsulting.com or rjohnson@alacritaconsulting.com , +44(0)207-691-4915



'/>"/>
SOURCE Alacrita
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
2. Yongye Biotechnology International Retains CCG Investor Relations
3. ThirdBiotech Announces Kemeta as Newest Sponsor
4. Sinovac Biotech Ltd. Schedules 2007 Annual Meeting of Shareholders
5. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial
6. Yongye Biotechnology International Announces Conference Call to Discuss Second Quarter 2008 Results
7. Tiens Biotech Group (USA) Reports Second Quarter and Six-Month Results
8. China Kangtai Cactus Biotech Announces Record Second Quarter Results
9. Yongye Biotechnology International Announces Second Quarter Results
10. BeaconEquity.com Issues Trade Alerts on Biotechnology Stocks: ELN, PFE, AMGN, DNA, BIIB, GILD
11. Lixte Biotechnology Holdings Announces Filing of a New Patent Application for Cancer Therapy Based on Targeting a Biomarker by Novel Investigational Agents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/11/2017)... ... ... Algenist continues to disrupt the skincare industry with today’s debut of GENIUS Liquid ... the key structural element skin needs to maintain its youthful appearance and Algenist is ... First to market with proprietary collagen water active , Active ...
(Date:8/10/2017)... ... August 09, 2017 , ... Teachers from three Philadelphia middle ... 14th through the 16th, the University City Science Center will kick off the ... provides Philadelphia-based middle school educators an opportunity for professional development related to STEM ...
(Date:8/10/2017)... ... August 09, 2017 , ... Okyanos Center for Regenerative Medicine has announced its ... Hotel in Freeport, Grand Bahama on September 27, 2017. This daytime event is free ... from the Ministry of Health’s National Stem Cell Ethics Committee (NSCEC) and regulations laid ...
(Date:8/10/2017)... USA, and CARDIFF, UK (PRWEB) , ... August ... ... and photonics, has announced an agreement establishing Kinokuniya Company Ltd. as its exclusive ... SPIE as the exclusive sales representative for the SPIE Digital Library in Japan. ...
Breaking Biology Technology:
(Date:5/23/2017)...  Hunova, the first robotic gym for the rehabilitation and functional motor ... Genoa, Italy . The first 30 robots will be ... USA . The technology was developed and patented at the ... spin-off Movendo Technology thanks to a 10 million euro investment from entrepreneur ... ...
(Date:4/19/2017)... 2017 The global military biometrics ... marked by the presence of several large global players. ... five major players - 3M Cogent, NEC Corporation, M2SYS ... nearly 61% of the global military biometric market in ... global military biometrics market boast global presence, which has ...
(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...
Breaking Biology News(10 mins):